Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A15 | Q9H2J7 | 13/20 | 0.80 |
| ▸ | HRH1 | P35367 | 10/20 | 0.80 |
| ▸ | MEN1 | O00255 | 1/20 | 0.75 |
| ▸ | NPC1 | O15118 | 1/20 | 0.75 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.75 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.75 |
| ▸ | GMNN | O75496 | 1/20 | 0.75 |
| ▸ | USP2 | O75604 | 1/20 | 0.75 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.75 |
| ▸ | LMNA | P02545 | 1/20 | 0.75 |
| ▸ | TP53 | P04637 | 1/20 | 0.75 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.75 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.75 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.75 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.75 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.75 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.75 |
| ▸ | MAPT | P10636 | 1/20 | 0.75 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.75 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.75 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5473193 | 0.92 | SLC6A15 (0.82) | SLC6A15HRH1MEN1NPC1CACNA1F | |
| SCHEMBL31294067 | 0.89 | SLC6A15 (1.00) | SLC6A15HRH1MEN1NPC1CACNA1F | |
| SCHEMBL29687346 | 0.88 | HRH1 (1.00) | SLC6A15HRH1MEN1NPC1CACNA1F | |
| SCHEMBL29687620 | 0.88 | HRH1 (0.76) | SLC6A15HRH1MEN1NPC1CACNA1F | |
| SCHEMBL24363099 | 0.88 | HRH1 (0.76) | SLC6A15HRH1MEN1NPC1CACNA1F | |
| SCHEMBL7818381 | 0.86 | SLC6A15 (0.60) | SLC6A15HRH1PTAFR | |
| Loratadine SCHEMBL3862958 | 0.86 | SLC6A15 (1.00) | SLC6A15HRH1MEN1NPC1CACNA1F | |
| Loratadine SCHEMBL29380223 | 0.86 | SLC6A15 (1.00) | SLC6A15HRH1MEN1NPC1CACNA1F | |
| Loratadine SCHEMBL4596 | 0.86 | SLC6A15 (1.00) | SLC6A15HRH1MEN1NPC1CACNA1F | |
| Loratadine SCHEMBL29441811 | 0.86 | SLC6A15 (1.00) | SLC6A15HRH1MEN1NPC1CACNA1F |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1123931-B1 | Tricylic amide and urea compounds useful for inhibition of G-protein function and for treatment of proliferative diseases | SCHERING CORP (US) | 2005-06-01 | — | — | EP | disclosed |
| US-6492381-B1 | Tricyclic carbamate compounds useful for inhibition of G-protein function and for treatment of proliferative diseases | SCHERING CORP. | 2002-12-10 | — | — | US | disclosed |
| US-20020068742-A1 | Tricyclic amide and urea compounds useful for inhibition of G-protein function and for treatment of proliferative diseases | BISHOP W ROBERT (US) | 2002-06-06 | — | — | US | disclosed |
| US-6365588-B1 | AS ANTINEOPLASTIC AGENT AND A POTENTIATING | SCHERING CORPORATION | 2002-04-02 | — | — | US | disclosed |
| EP-0723540-B1 | TRICYCLIC AMIDE AND UREA COMPOUNDS USEFUL FOR INHIBITION OF G-PROTEIN FUNCTION AND FOR TREATMENT OF PROLIFERATIVE DISEASES | SCHERING CORP (US) | 2001-12-12 | — | — | EP | disclosed |
| US-6300338-B1 | AS ANTITUMOR AGENT | SCHERING CORPORATION | 2001-10-09 | — | — | US | disclosed |
| EP-1123931-A1 | Tricylic amide and urea compounds useful for inhibition of G-protein function and for treatment of proliferative diseases | SCHERING CORPORATION (US) | 2001-08-16 | — | — | EP | disclosed |
| US-6242458-B1 | INHIBITING FARNESYL PROTEIN TRANSFERASE IN A HUMAN | SCHERING CORPORATION | 2001-06-05 | — | — | US | disclosed |
| US-6075025-A | Tricyclic carbamate compounds useful for inhibition of G-protein function and for treatment of proliferative diseases | SCHERING CORPORATION (US) | 2000-06-13 | — | — | US | disclosed |
| US-5977128-A | ENZYME INHIBITORS | SCHERING CORPORATION (US) | 1999-11-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020068742-A1 | Tricyclic amide and urea compounds useful for inhibition of G-protein function and for treatment of proliferative diseases | RASGRP1, CCNA1, CCNA2 | SLC6A15 1804/4885HRH1 389/4885MEN1 485/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.